Guest guest Posted August 21, 2008 Report Share Posted August 21, 2008 http://seekingalpha.com:80/article/91907-micromet-another-seal-of-approval The BiTE platform represents a truly novel class of anti-cancer agents and is not like anything else out there. It facilitates the construction of bi-specific antibodies that simultaneously bind cancer cells and the body's most potent immune cells (T cells), All the best, ~ Karl Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.